Eli Lilly entered into an underwriting agreement on August 18, 2025 and agreed to issue and sell 7 series of notes, including Floating Rate Notes due 2028 of $750,000,000 and 4.000% Notes due 2028 of $1,000,000,000.

1. 01

   Eli Lilly entered into an underwriting agreement on August 18, 2025 and agreed to issue and sell 7 series of notes, including Floating Rate Notes due 2028 of $750,000,000 and 4.000% Notes due 2028 of $1,000,000,000.

2. 02

   The company said the Floating Rate Notes accrue interest at a floating rate equal to Compounded SOFR plus 0.530%, with maturity on October 15, 2028, and the fixed rate notes range from 4.000% (maturing 2028) to 5.650% (maturing 2065).

3. 03

   The company said the offering of the notes closed on August 20, 2025, and net proceeds, after deduction of underwriting discounts and before deduction of estimated offering expenses, were approximately $6.71 billion.

4. 04

   Eli Lilly said it may redeem the fixed rate notes, in whole or in part, on the terms and conditions set forth in the notes, but may not redeem the Floating Rate Notes at its option prior to maturity. It added that upon the occurrence of an Event of Default, the principal amount of the notes of that series may be declared immediately due and payable.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.